MVASI® IS APPROVED FOR THE TREATMENT OF 6 DIFFERENT CANCER TYPES 1
For information about your specific diagnosis, please make a selection below:
YOUR DOCTOR HAS SAID THAT YOU HAVE OC
OC starts in the cells of the ovaries or the fallopian tubes. Some types of ovarian tumors are benign, but some are cancerous and may spread beyond the ovaries. 2
EACH OF THE 3 OVARIAN CELL TYPES DEVELOPS INTO A UNIQUE TUMOR TYPE: EPITHELIAL, GERM CELL, AND STROMAL 2
Epithelial ovarian, fallopian tube, and primary peritoneal cancers are related and treated similarly.3
Epithelial ovarian carcinomas account for up to 90% of malignant (cancerous) ovarian tumors, which begin forming on the surface of the ovaries. 2
Fallopian tube canceris a rare form of cancer that starts in the fallopian tube and has similar symptoms to ovarian cancer. 2
Primary peritoneal carcinomais another form of cancer that begins in the cells inside the fallopian tubes and spreads throughout the pelvis and abdomen. 2
WORKING WITH YOUR OVARIAN CANCER DOCTORS AND SPECIALISTS
Because ovarian cancer can impact you and your loved ones' lives, it is important to work closely with your health care team. If you have questions, reach out to your doctor’s office directly for more information.
Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI® by these organizations.
Visit these websites for more information about OVARIAN CANCER
Important Safety Information
Possible serious side effects
Everyone reacts differently to MVASI® therapy. So, it's important to know what the side effects are. Although some people may have a life-threatening side effect, most do not. Your doctor will stop treatment if any serious side effects occur. Be sure to contact your health care team if there are any signs of these side effects.
Side effects seen most often
In clinical studies across different types of cancer, some patients experienced the following side effects:
MVASI® is not for everyone
Talk to your doctor if you are:
For more information about your treatment or condition, talk to your doctor.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Amgen at 1-800-772-6436.
Please see full Product Information for additional Important Safety Information.
Metastatic Colorectal Cancer (mCRC)
MVASI® is approved to treat metastatic colorectal cancer (mCRC) for:
MVASI® is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body.
Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
MVASI®, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous non-small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease.
Recurrent Glioblastoma (rGBM)
MVASI® is approved to treat recurrent glioblastoma in adults.
Metastatic Renal Cell Carcinoma (mRCC)
MVASI®, used with interferon alfa, is approved to treat metastatic kidney cancer (mRCC).
Advanced Cervical Cancer (CC)
MVASI®, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix.
Ovarian Cancer (OC)
MVASI®, in combination with carboplatin and paclitaxel, followed by Avastin alone, is used for the treatment of patients with advanced (Stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgery.
MVASI®, in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan, is approved to treat platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in women who received no more than two prior chemotherapy treatments.
MVASI®, either in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine, followed by Avastin alone, is approved for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
References: 1. MVASI® (bevacizumab-awwb) Prescribing Information, Amgen. 2. American Cancer Society. What is Ovarian Cancer?Accessed February 15, 2022. 3. National Cancer Institute. Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)-Health Professional Version. Accessed February 15, 2022.